Overview
The diabetes mellitus epidemic is unfolding across the globe with the World Health Organization (WHO) reporting a worldwide prevalence of 177 million patients with diabetes. Type 2 diabetes accounts for approximately ninety percent of all diabetes cases. Long-term complications of type 2 diabetes include atherosclerosis, heart disease, stroke, end-stage renal disease, retinopathy leading to blindness, nerve damage, sexual dysfunction, frequent infections, and difficult-to-treat foot ulcers, sometimes resulting in lower limb amputation. Diabetics are twice as likely to develop cardiovascular disease or have a stroke, two to six times more likely to have transient ischemic attacks, and fifteen to forty times more likely to require lower-limb amputation compared with the general population. In 2002, the total economic cost of diabetes was estimated to be $132 billion accounting for one in every ten health care dollars spent in the United States. As a direct consequence of this economic impact and in light of the fact that current approved therapies fail to provide adequate therapeutic advantage in preventing hyperglycemia, industry has been heavily focused on addressing new fundamental cellular mechanisms that will potentially address this unmet need. New Therapeutic Strategies for Type 2 Diabetes provides the reader with the most comprehensive survey to-date of the most innovative small molecule research strategies targeted at treating the burgeoning type 2 diabetes epidemic. Each chapter is written by a recognised thought-leader in this field. The book will be an invaluable reference for researchers and medicinal chemists that concisely explains the biological mechanisms underpinning each cutting-edge therapeutic strategy along with key medicinal chemistry rationales and up-to- date clinical findings.
Full Product Details
Author: Rob M Jones (Arena Pharmaceuticals) ,
David E. Thurston ,
David P. Rotella ,
Salvatore Guccione
Publisher: Royal Society of Chemistry
Imprint: Royal Society of Chemistry
Volume: Volume 27
Dimensions:
Width: 15.60cm
, Height: 3.70cm
, Length: 23.40cm
Weight: 0.975kg
ISBN: 9781849734141
ISBN 10: 1849734143
Pages: 532
Publication Date: 05 September 2012
Audience:
Professional and scholarly
,
Professional & Vocational
Format: Hardback
Publisher's Status: Active
Availability: Out of stock
The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available.
Reviews
Current research efforts in this direction,using small-molecule approaches,are outstandingly reviewed in the book edited by Dr. Robert M. Jones, providing deep understanding of the recent advance in T2DM drug development and delivery. The book comprises of authoritative reference texts encompassing the evolution, progress and challenges in front of the key leading drug candidates. The reader is easily able to follow each compound's development from its conception to its progression,modification, underlying mechanisms of action and current state of development. In addition, various aspects of future research are discussed. In conclusion, this book can be unreservedly recommended to everyone interested in drug research and discovery in T2DM. It is timely and useful, serving as a desktop reference for quick updates, as a detailed information source for specific therapeutic agents, and as a practical guide for research activities. -- Dr. Sofiya Gancheva, Prof. Dr. Michael Roden, German Diabetes Center and Clinics of Endocrinology and Diabetology(Germany) ChemMedChem 2013, 8, 1415 - 1418
"""Current research efforts in this direction,using small-molecule approaches,are outstandingly reviewed in the book edited by Dr. Robert M. Jones, providing deep understanding of the recent advance in T2DM drug development and delivery. The book comprises of authoritative reference texts encompassing the evolution, progress and challenges in front of the key leading drug candidates."" ""The reader is easily able to follow each compound’s development from its conception to its progression,modification, underlying mechanisms of action and current state of development. In addition, various aspects of future research are discussed."" ""In conclusion, this book can be unreservedly recommended to everyone interested in drug research and discovery in T2DM. It is timely and useful, serving as a desktop reference for quick updates, as a detailed information source for specific therapeutic agents, and as a practical guide for research activities."" -- Dr. Sofiya Gancheva, Prof. Dr. Michael Roden, German Diabetes Center and Clinics of Endocrinology and Diabetology(Germany) * ChemMedChem 2013, 8, 1415 - 1418 *"
""Current research efforts in this direction,using small-molecule approaches,are outstandingly reviewed in the book edited by Dr. Robert M. Jones, providing deep understanding of the recent advance in T2DM drug development and delivery. The book comprises of authoritative reference texts encompassing the evolution, progress and challenges in front of the key leading drug candidates."" ""The reader is easily able to follow each compound’s development from its conception to its progression,modification, underlying mechanisms of action and current state of development. In addition, various aspects of future research are discussed."" ""In conclusion, this book can be unreservedly recommended to everyone interested in drug research and discovery in T2DM. It is timely and useful, serving as a desktop reference for quick updates, as a detailed information source for specific therapeutic agents, and as a practical guide for research activities."" * ChemMedChem 2013, 8, 1415 - 1418 *
Current research efforts in this direction,using small-molecule approaches,are outstandingly reviewed in the book edited by Dr. Robert M. Jones, providing deep understanding of the recent advance in T2DM drug development and delivery. The book comprises of authoritative reference texts encompassing the evolution, progress and challenges in front of the key leading drug candidates. The reader is easily able to follow each compound's development from its conception to its progression,modification, underlying mechanisms of action and current state of development. In addition, various aspects of future research are discussed. In conclusion, this book can be unreservedly recommended to everyone interested in drug research and discovery in T2DM. It is timely and useful, serving as a desktop reference for quick updates, as a detailed information source for specific therapeutic agents, and as a practical guide for research activities. -- Dr. Sofiya Gancheva, Prof. Dr. Michael Roden, German Diabetes Center and Clinics of Endocrinology and Diabetology(Germany) * ChemMedChem 2013, 8, 1415 - 1418 *
Author Information
Robert M. Jones is currently Senior Director of Medicinal Chemistry at Arena Pharmaceuticals and also serve as Adjunct Faculty to the University of Mississippi, Department of Medicinal Chemistry. He has been an active medicinal chemistry researcher for the past 16 years, 13 of which have been in industry. Over the past 8 years his research has focused on metabolic diseases in particular Type 2 Diabetes. His work has led to several compounds entering or being nominated for clinical development, including a first in class GPR119 agonist for T2D. He has also been cited as an inventor of ~ 63 patents / provisional filings; and has published ~ 60 manuscripts and abstracts in the field of medicinal chemistry.
